Key Insights

Highlights

Treatment Research

5 treatments under study, led by Bevacizumab

Research Leaders

5 sponsors active, led by Maastricht University Medical Center

Related Conditions

Often studied with 5 related conditions

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 100/100

Termination Rate

33.3%

1 terminated out of 3 trials

Success Rate

0.0%

-86.6% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed with results

Key Signals

1 with results0

Data Visualizations

Phase Distribution

3Total
Not Applicable (1)
P 1 (1)
P 2 (1)

Trial Status

Recruiting1
Terminated1
Withdrawn1

Clinical Trials (3)

Showing 3 of 3 trials
NCT07224464Not ApplicableRecruiting

The Sarah Nanotechnology System for Treatment of Advanced Metastatic Solid Tumors Using Hyperthermia.

NCT00408070Phase 2Terminated

Bevacizumab Study With Carboplatin & Paclitaxel in Ovarian, Fallopian Tube or Primary Peritoneal Cancer

NCT00935142Phase 1WithdrawnPrimary

Non-invasive Imaging With [18F]VM4-037

Showing all 3 trials

Research Network

Common Treatments

  • Bevacizumab1
  • 18fvm40371
  • Carboplatin1
  • The Sarah Nanotechnology System Intended To Deliver Thermal Energy To Malignant Cells For The Purpose Of Thermal Destruction Of These Cells In Patients With Advanced Metastatic Solid Tumors1
  • Paclitaxel1

Active Sponsors

  • Maastricht University Medical Center1
  • Maastricht Radiation Oncology1
  • New Phase Ltd1
  • Genentech Inc1
  • Uconn Health1

Related Conditions

  • Ovarian Cancer1
  • Metastatic Solid Tumors1
  • Fallopian Tube Cancer1
  • Peritoneal Cancer1
  • Stage 3 Cancer1

Activity Timeline